# Repligen Corporation (RGEN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $167.60, market value $9.5 billion.

## Valuation
- **P/E (trailing): 226.5×** (5-yr avg 161.6×, 3-yr avg 238.0×). Repligen Corporation trades at 226.5× trailing earnings, well above its own five-year average of 161.6×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 63.5×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.22**. A PEG of 0.22 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 12.0×**. Each dollar of revenue is priced at 12.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.5×**. The shares trade at 4.5× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 65.8×**. Enterprise value is 65.8× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.2%** (5-yr avg 1.0%). Free cash flow equals 1.2% of the market value, above its five-year average of 1.0%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 0.4%**. The inverse of the P/E: 0.4% of the price is earned each year.

## Profitability
- **Operating margin: 8.2%**. 8.2% of revenue is left after running the business.
- **Net margin: 6.6%**. 6.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 2.3%**. 2.3% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 2.5%**. Return on all capital, debt included, is 2.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 1.4%**. Each dollar of assets produces 1.4% of profit.

## Growth
- **Revenue growth (1 yr): 16.4%** (3-yr -2.7%/yr, 5-yr 15.0%/yr). Revenue grew 16.4% over the last year, against 15.0% a year compounded over five years.
- **EPS growth (1 yr): 287.0%** (3-yr -35.7%/yr, 5-yr -5.0%/yr). Earnings per share rose 287.0%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 2.5%/yr**. Free cash flow has compounded at 2.5% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.26**. Debt is 0.26 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Repligen Corporation holds more cash than debt.
- **Altman Z-score: 8.04**. A Z-score of 8.04 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Repligen Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (20 analysts). 20 analysts cover Repligen Corporation; the consensus is strong_buy, with an average price target of $187.70 (+12% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 39.0%** (YTD 2.3%, 3-mo 37.0%). The shares are up 39.0% over twelve months including dividends.
- **From 52-week high: -11.2%** (66.0% above the low). Trading 11% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 1.29** (volatility 46%). Beta of 1.29 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RGEN · Page: https://foliofundamentals.com/stocks/rgen

Not investment advice.